| Ytd | -94.15% | |
| 1y | -89.58% |
| Open | 0.18 | Prev Close | 0.18 | Low | 0.17 | High | 0.18 | Mkt Cap | 88.68M |
| Vol | 3.75M | Avg Vol | 26.13M | EPS | -0.79 | P/E | -0.23 | Forward P/E | -1.24 |
| Beta | 2.04 | Short Ratio | 6.29 | Inst. Own | 77.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 0.17 | 200-d Avg | 1.32 | 1yr Est | 7.61 |
NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves
Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings pag
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-
Top Wall Street analysts upgraded Grupo Cibest, Lufax, Honeywell, and Gossamer Bio. JBS also receive
Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and
Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market sess
Gossamer Bio Inc. (NASDAQ:GOSS) stock is trading higher on Monday as the company is preparing to sub
Gossamer Bio plans a September 2026 NDA filing for seralutinib following FDA feedback and reacquires
Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a
Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Cap
Gainers Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 59.7% to $0.39 during Monday's
Special Meeting: Approval of Proposals Related to Convertible Note Exchange and Reverse Stock SplitA
– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutin
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a bioph
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a bioph
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a bioph
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a bioph
[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potent
NEW YORK--(BUSINESS WIRE)---- $GOSS #Bio--Faruqi & Faruqi, LLP, a leading national securities law fi
New York, New York--(Newsfile Corp. - June 1, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nation
NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recogni
[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, reminds investors o
LOS ANGELES--(BUSINESS WIRE)---- $GOSS--GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. S
LOS ANGELES, June 01, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors th
GOSS DEADLINE ALERT: Hagens Berman Alerts Gossamer Bio (GOSS) Investors to Today's Lead Plaintiff De
SAN FRANCISCO, June 1, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against
Gossamer Bio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Ri
LOS ANGELES, June 1, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action laws
LOS ANGELES, May 31, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights lit
Top Wall Street analysts changed outlook on top names, downgrading ZBH, GOSS, TRI, PCG, and BOX. See
Health care sector has oversold stocks, RSI momentum indicator can help traders predict short term p
On Thursday, 369 companies hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
On Tuesday, 91 stocks hit new 52-week lows.
Thursday's session saw 337 companies set new 52-week lows.
On Friday, 497 companies set new 52-week lows.
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the co